Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models

Documenti analoghi

• Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
  di: LaPensee, Ken, et al.
  Pubblicazione: (2018)
• 1462. Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia Who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
  di: Lodise, Thomas, et al.
  Pubblicazione: (2018)
• Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
  di: LaPensee, Kenneth, et al.
  Pubblicazione: (2019)
• Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
  di: Lodise, Thomas P., et al.
  Pubblicazione: (2021)
• Correction to: Decision Analysis: Omadacycline Relative to Moxifoxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difcile Infection
  di: Lodise, Thomas P., et al.
  Pubblicazione: (2021)